Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab

By afschroeder • August 20, 2025

Cheon J, Ryoo BY, Chon HJ, Kim HD, Ryu MH, Kim KP, Kang B, Finn RS, Chan SL, Yoo C. Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab. Liver Cancer. 2025 Jan 21;14(4):446-455. doi: 10.1159/000543666. PMID: 40831890; PMCID: PMC12360742.

Tags: Atezolizumab, Bevacizumab, Hematology/Oncology, Hepatocellular carcinoma, Publications, regorafenib, Tyrosine kinase inhibitor

Related Posts

Results from a Phase II Single Arm Trial Evaluating the Safety and Efficacy of Anhydrous Enol-Oxaloacetate on Improving Cognitive Complaints in Breast Cancer Survivors

Ganz PA, Van Dyk K, Crespi CM, Petersen L, Sedrak MS, Bower JE. Results from a Phase II Single Arm Trial Evaluating the Safety and[...]

Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 Study

McKean M, Chmielowski B, Butler MO, Carvajal RD, Rodon J, Carlino MS, Kim KB, Wise-Draper TM, Khan S, Salama AKS, Moser J, Ang A, Barrios[...]

Conversational artificial intelligence for geriatric screening: A mixed-methods feasibility study

Naeim A, Cheng J, Spiegel B, Bakshian A, Tetrault E, Mehra M, Amini D, Krut Z, Shang H, Sedrak MS, Bui A, Johnson T, Wang[...]